商品编号


CHI-HF-21035-C025



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

25 ?g

商品信息


More Information



Product Details



Synonyms

Interleukin-35



Product Type

Protein



Properties



Source/Host

CHO cells



Sequence

The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1.



Crossreactivity

Human



BIOLOG
ical Activity

Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells.



Purity

≥98% (SDS-PAGE)



Endotoxin Content

<0.06eu mu;g="" protein="" (lal="" test;="" lonza).="">0.06eu>



Reconstitution

Reconstitute at 100μg/ml in sterile PBS.



Formulation

Lyophilized from 0.2μm-filtered solution in PBS.



Other Product Data

NCBI reference NP_005746.2: Ebi3 subunit (human)
NCBI reference NP_000873.2: IL-12a subunit (human)



Declaration

Manufactured by Chimerigen.



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells'
ABI
lity to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.


Product References

EBI3 downregulation contributes to type I collagen overexpression in scleroderma skin: H. Kudo, et al.; J. Immunol.
195,
3565 (2015)

A potential immunopathogenic role for reduced IL-35 expression in allergic asthma: W. Wang, et al.; J. Asthma
52,
763 (2015)